

S.18

Current Costs of Inhaled Nicotine

Prospero B. Gogo, Jr., MD, FACC


Professor of Medicine

Director, Cardiac Cath Lab; Director, Fellowship in Interventional Cardiology

UVMHC/Larner College of Medicine


Vaping and Smoking Harms Vermonters

Case Mix, UVMMC vs. US




n=1014

● Elective ● MI




n=702,928



n=678

56% of Vermonters with any history of cardiovascular disease are smokers (1)


40% of patients presenting with myocardial infarction requiring stenting are smokers (2)



1. Vermont Behavioral Risk Factor Surveillance System

2. NCDR-CathPCI data


STEMI OUTCOMES




*excludes patients with cardiac arrest and/or cardiogenic shock

Internal unadjusted All-STEMI mortality was 4.5% for all activations and 4.2% for CMS-eligible primary PCI

Medicare Reimbursement



Medicare Reimbursement



“Floor” of estimated spend is more than \$35 million per annum at UVMMC for treatment of coronary artery disease. The actual number may be significantly higher when other payers are factored in.

Statewide

- DRG 280, 281, 282, 283 (VUHDDS 2017)
- 457 Medicare-eligible admissions statewide in 2017
- \$4.8 million for this population in one year
- Does not include private payers

SIDS
Uterine cancer
Low birth weight
Bladder cancer
Congenital malformations
Renal carcinoma
Leukemia
Liver carcinoma
Colon cancer
Asthma
Emphysema
Small cell lung cancer
Pancreatic cancer
Stroke
Angina
Sudden Death
Congestive Heart Failure
Esophageal cancer
Chronic bronchitis
Coronary artery disease
Arrhythmia
Cervical cancer
Chronic obstructive pulmonary disease
Laryngeal cancer
Rectal cancer
Gastric cancer
Impaired fertility
Preterm delivery
Miscarriage